Company news
Siga Technologies Inc. (NASDAQ:SIGA) news
Every Siga Technologies Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
July 30, 2026
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
May 7, 2026
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
April 30, 2026
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update
March 10, 2026
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
March 3, 2026
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
November 6, 2025
SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
October 30, 2025
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
August 5, 2025
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
July 29, 2025
SIGA Reports Financial Results for Three Months Ended March 31, 2025
May 8, 2025
SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results
May 1, 2025
SIGA Declares Special Cash Dividend of $0.60 Per Share
April 8, 2025
SIGA Appoints Retired General John M. Keane to its Board of Directors
March 18, 2025
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024
March 11, 2025
SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results
March 4, 2025
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
January 2, 2025
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
December 10, 2024
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024
November 7, 2024
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
October 31, 2024
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
October 22, 2024
SIGA Announces Agreement to Supply TPOXX® in Morocco
October 8, 2024
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
August 21, 2024
Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released
August 15, 2024
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024
August 1, 2024
SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
July 25, 2024
SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®
July 19, 2024
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
June 17, 2024
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
June 10, 2024
SIGA Reports Financial Results for Three Months Ended March 31, 2024
May 7, 2024
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results
May 1, 2024
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
April 1, 2024
SIGA Names Larry Miller General Counsel
March 25, 2024
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
March 12, 2024
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
March 5, 2024
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
January 22, 2024
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
November 7, 2023
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
October 26, 2023
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries
October 23, 2023
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer
September 6, 2023
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023
August 8, 2023
SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results
July 27, 2023
SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®
July 27, 2023
SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium
June 27, 2023
SIGA Reports Financial Results for Three Months Ended March 31, 2023
May 4, 2023
SIGA Declares Special Cash Dividend of $0.45 Per Share
May 4, 2023
SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results
April 27, 2023
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022
March 2, 2023
SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023
January 17, 2023
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
November 3, 2022